Total Funding
78
49
Total FundingVenture - Series Unknown raised
Growth Score
-9 pts
Heat Score
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
883474
Cellartis develops human embryonic stem cells and technology for drug discovery research, toxicity testing and regenerative medicine.
Acquired by 
Cellectis
About the Company
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine
Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products
and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
